ORGO Earnings Date: Nov 5, 2026 (Estimated) — Organogenesis Holdings Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is ORGO's next earnings date?
Organogenesis Holdings Inc. (ORGO) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.17 on revenue of $52.1M.
How did ORGO do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Organogenesis Holdings Inc. posted EPS of -$0.69 versus the -$0.35 estimate, a miss of 97.1%. Revenue was $100.8M against a $54.3M estimate. The stock's 1-day post-earnings move was -22.8%.
How much does ORGO stock move after earnings?
ORGO beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 33.0% (up or down) in the day after earnings.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.35 | -0.69 | -97.14% | $100.8M | ❌ Miss | -22.82% | -26.97% | -29.05% |
| 2026-05-07 | Q1 2026 | -0.29 | -0.34 | -17.24% | $36.3M | ❌ Miss | -6.32% | +2.37% | -5.93% |
| 2026-02-26 | Q4 2025 | 0.21 | 0.40 | +90.48% | $225.6M | ✅ Beat | -13.24% | -21.62% | -38.11% |
| 2025-11-06 | Q3 2025 | 0.07 | 0.18 | +152.86% | $150.9M | ✅ Beat | +44.73% | +59.64% | +19.79% |
| 2025-02-27 | Q4 2024 | 0.02 | 0.07 | +250.00% | $126.7M | ✅ Beat | +102.28% | +83.55% | +46.58% |
| 2024-02-29 | Q4 2023 | 0.01 | 0.01 | +0.00% | $99.7M | ➖ Inline | -18.21% | -12.32% | -21.57% |
| 2023-08-09 | Q2 2023 | 0.02 | 0.05 | +150.00% | $117.3M | ✅ Beat | -18.88% | -23.01% | -25.37% |
| 2023-05-10 | Q1 2023 | -0.02 | -0.01 | +50.00% | $107.6M | ✅ Beat | +37.14% | +51.43% | +91.43% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $43.8M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 97.8% | $42.8M | -57.5% | — | — | $100.8M | $150.5M |
| Grant | 2.2% | $950K | +320.4% | — | — | $226K | $377K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.